A study to investigate the long-term safety and efficacy of belimumab in adults with systemic sclerosis associated interstitial lung disease

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

This study is an open label extension study of an ongoing randomized controlled clinical study, 218224 which aims to assess the efficacy of belimumab on reducing the decline in lung function in participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 02 Apr 2026. Study ID: 25-0741
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research